- Theralase Technologies (TLT) has closed a non-brokered private placement offering for gross proceeds of $2,500,000
- On closing, the corporation issued a total of 10,000,000 units at a price of $0.25 per unit
- The company intends to use the proceeds of the offering to fund several clinical studies
- Theralase Technologies is a clinical-stage pharmaceutical company focused on light-activated photodynamic compounds
- Theralase (TLT) opened trading at C$0.25
Theralase Technologies (TLT) has closed a non-brokered private placement offering for gross proceeds of $2,500,000.
On closing, the corporation issued a total of 10,000,000 units at a price of $0.25 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of $0.35 per share for a period of 24 months following the date of issuance.
Theralase paid a finder’s fee of $10,167 in cash and 76,800 common shares and issued 58,734 finder’s warrants.
The company intends to use the proceeds of the offering to fund several clinical studies.
All securities issued will be subject to a statutory four-month hold period, expiring on January 22, 2023.
Theralase Technologies is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated photodynamic compounds.
Theralase (TLT) opened trading at C$0.25.
